



## **Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting**

October 8, 2020

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the virtual Joint 49<sup>th</sup> Annual Child Neurology Society & 16<sup>th</sup> International Child Neurology Society Congress (CNS-ICNA) Meeting. The CNS-ICNA annual meeting is being held virtually from October 12<sup>th</sup> through October 23<sup>rd</sup>, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation on Monday October 12<sup>th</sup> at <http://zynerba.com/publications/>.

*Title: "ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker"*

*Abstract number: 0406 0585 000889*

*Primary keyword: "Cognitive/Behavioral Disorders (including Autism)"*

*Poster number: 678*

*Title: "Tolerability and Efficacy of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study [BRIGHT (ZYN2-CL-030)]"*

*Abstract number: 0406 0585 000888*

*Primary keyword: "Cognitive/Behavioral Disorders (including Autism)"*

*Poster number: 677*

### **About Zynerba Pharmaceuticals, Inc.**

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at [www.zynerba.com](http://www.zynerba.com) and follow us on Twitter at @ZynerbaPharma.

### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. These and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

### **Zynerba Contact**

Will Roberts, VP Investor Relations and Corporate Communications

484.581.7489

[robertsw@zynerba.com](mailto:robertsw@zynerba.com)

### **Media contact**

Molly Devlin

Evoke KYNE

215.928.2199

[Molly.Devlin@evokegroup.com](mailto:Molly.Devlin@evokegroup.com)